-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Latest From Biotech Now
Governors Share Best Practices on Bringing Biotech Jobs to their States
With the state competition for biotech jobs in full force at the BIO International Convention, BIO released its Bioscience Economic Development report yesterday to a standing room only crowd that came to hear Texas Gov. Rick Perry, Pennsylvania Gov. Tom Corbett, Missouri Gov. Jay Nixon and Director of Illinois Department of Commerce and Economic Opportunity Jack Lavin share their insights on attracting and growing the biotech industry within their states. Common themes quickly emerged around Read More >
AquAdvantage Salmon: A Regulatory Odyssey
At BIO 2012, an article was published on AquaBounty Technologies which told the tale of the Company’s New Animal Drug Application (NADA) for AquAdvantage Salmon. At that time, the Company had completed all the required major elements for an FDA approval and FDA had held a thorough public airing before its Veterinary Medicine Advisory Committee (VMAC) of the results of the agency’s Center for Veterinary Medicine’s (CVM) review of AquaBounty’s application. Following the meeting of Read More >
Alzheimer’s Disease “Robs You of Everything”
George Hendrick and his wife, Mary Lee, experienced the typical highs and lows of parenthood as they raised nine children in New Lenox, a south suburb of Chicago. After the couple’s nest was nearly empty, in what was supposed to be their golden years, George was told he had memory and thinking problems, and later, Alzheimer’s disease. George’s long tenure as a Will County police officer was cut short. He could no longer carry a gun, and Read More >
Venture Capital Trends
With industry data and numbers, results are always a mixed bag, says David Thomas, BIO’s Director of Industry Research & Analysis – and the latest on venture capital trends is no exception. In the U.S., biotech VC funding is flat, and start-up money is drying up. According to the National Venture Capital Association (NCVA), U.S. VC funding for biotech fell to $4.1 billion in 2012 (figure 1). This 17% drop was greater than the 10% Read More >
Biomedical R&D in the 21st Century
Reflecting back upon my career, I recognize the importance academic-industry research partnerships played in shaping my philosophy as a scientist and research leader. Something deeply fulfilling happens when basic and applied scientists ally, and our individual passion to make a difference in the life of a patient merges into a community effort. We are moving ever closer to solving some of the toughest biomedical challenges of our time. But this is also an era of Read More >
